Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
JAMA Oncology|May 18, 2023
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialStefania Napolitano, Vincenzo De Falco, Giulia Martini, et al.
Cancers|May 14, 2022
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR ImmunohistochemistryFederica Zito Marino, Martina Amato, Andrea Ronchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2024
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE StudyCarlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.
Cancers|October 11, 2019
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution ExperiencePietro Paolo Vitiello, Vincenzo De Falco, Emilio Francesco Giunta, et al.
Molecular Cancer Therapeutics|March 3, 2019
EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal CancerGiulia Martini, Claudia Cardone, Pietro Paolo Vitiello, et al.
Clinical Colorectal Cancer|September 13, 2020
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal CancerFederica Tosi, Andrea Sartore-Bianchi, Sara Lonardi, et al.
ESMO Open|April 3, 2020
Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'Vincenzo De Falco, Luca Poliero, Pietro Paolo Vitello, et al.
ESMO Open|July 19, 2018
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancerBeatrice Borelli, Roberto Moretto, Sara Lonardi, et al.
Targeted Oncology|February 12, 2024
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus DurvalumabMargherita Rimini, Eleonora Loi, Mario Domenico Rizzato, et al.
The Lancet. Oncology|April 25, 2016
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, et al.
Pageof 17